JAK2 and ALK2 inhibitors and methods for their use
View Patent ↗Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
1. A compound having the following structure:
2. A pharmaceutically acceptable salt of a compound having the following structure:
3. The pharmaceutically acceptable salt of claim 2 , wherein the pharmaceutically acceptable salt is an acid addition salt.
4. The pharmaceutically acceptable salt of claim 3 , wherein the acid addition salt is a hydrochloric acid salt.
5. The pharmaceutically acceptable salt of claim 3 , wherein the acid addition salt is a fumaric acid salt.
6. A pharmaceutical composition comprising a compound having the following structure:
and a pharmaceutically acceptable carrier, diluent or excipient.
7. A pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound having the following structure:
and a pharmaceutically acceptable carrier, diluent or excipient.
8. The pharmaceutical composition of claim 7 , wherein the pharmaceutically acceptable salt is an acid addition salt.
9. The pharmaceutical composition of claim 8 , wherein the acid addition salt is a hydrochloric acid salt.
10. The pharmaceutical composition of claim 8 , wherein the acid addition salt is a fumaric acid salt.